Phase 2 N=50 Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas
Lymphoma
Primary: Mobilization Rate — 50 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=37 Health Coaching & Technology in a Weight Loss Center
Obesity · Technology · Videoconferencing
Primary: Completion Rate: Number of Participants Completing the Intervention — 6; 14; 7 Participants
N/A N=19 Activating and Identifying Neural Responses to Social Rejection: a Combined tDCS and fMRI Study
Healthy
Primary: Blood Oxygen Level Dependent (BOLD) Signal Changes (in Arbitrary Units) — .57; .66; .25; .29 Arbitrary units
Phase 4 N=162 Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO
Central Retinal Vein Occlusion
Primary: The Proportion of Participants Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) on the Early Treatment Diabetic Retinopathy Score (ETDRS) Chart Compared to…
Phase 3 N=463 A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
Migraine
Primary: Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days — -1.02; -4.14 Days — p=<0.0001
N/A N=20 A Proof of Concept Study to Investigate the Use and Relevance of a Digital Platform for Infant Crying and Fussing
Healthy
Primary: The Rating by the Primary Caregivers on the Use and Relevance of the Cry and Fuss Clock Generated From the LENA Recorder Data and the Rating by the Primary Caregiver on…
Phase 2 N=30 Botulinum Toxin for Pelvic Pain in Women With Endometriosis
Endometriosis · Chronic Pelvic Pain · Pelvic Muscle Spasm
Primary: Number of Participants With Improvement in Pain — 11; 4 Participants
N/A N=54 Impact of Exercise Training on Pain and Brain Function in Gulf War Veterans
Chronic Musculoskeletal Pain
Primary: Short Form McGill Pain Questionnaire Visual Analog Scale (VAS). — 29.82; 37.08; 30.07; 31.46 units on a scale — p=0.680
Phase 1 N=84 Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Malignant Melanoma
Primary: Maximum Tolerated Dose (MTD) of IMCgp100 Administered Weekly (Dose Escalation Part) — 600 ng/kg
N/A N=80 RF Power, LSI and Oesophageal Temperature Alerts During AF Ablation (PiLOT-AF Study)
Atrial Fibrillation
Primary: Rate of Oesophageal Temperature Alerts During Radiofrequency Energy (RF) Ablation on the Left Atrial (LA) Posterior Wall — 18; 18; 19; 19 Participants
Phase 4 N=11 Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients
Gastrointestinal Symptoms · Heart Transplantation
Primary: GI Tolerability as Measured by GSRS — 55.67; 34.17 score on a scale
N/A N=204 Pipeline Flex With SHield Technology Embolization - An International MulticEnter ObservationaL Post Market StuDy
Intracranial Aneurysm
Primary: Safety - Stroke/Death Occurrence — 3.23 percentage of patients with event — p=<0.001
N/A N=29 Calcium Absorption in Patients With Rothmund-Thomson Syndrome
Rothmund-Thomson Syndrome
Primary: Bone Density (Low Areal Bone Mineral Density (aBMD)) — -1.3; -0.9; -2.4; -1.2 z-score
N/A N=106 North Carolina Newborn Exome Sequencing for Universal Screening
Metabolism, Inborn Errors · Hearing Loss · Hereditary Disease
Primary: Parental Choices Following Decision Aid — 120; 57; 25; 2 Participants
N/A N=71 Perioperative Virtual Reality for Pediatric Anesthesia
Anxiety
Primary: Perioperative Pediatric Anxiety (Change From Baseline) — 0.0; 5.0 units on a scale